These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30720574)

  • 21. Increase in the OCT angiographic peripapillary vessel density by ROCK inhibitor ripasudil instillation: a comparison with brimonidine.
    Chihara E; Dimitrova G; Chihara T
    Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1257-1264. PubMed ID: 29520478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial.
    Sakamoto E; Ishida W; Sumi T; Kishimoto T; Tada K; Fukuda K; Yoneda T; Kuroiwa H; Terao E; Fujisawa Y; Nakakura S; Jian K; Okumichi H; Kiuchi Y; Fukushima A
    Sci Rep; 2019 Mar; 9(1):3755. PubMed ID: 30842572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraocular pressure-lowering effects of Ripasudil: a potential outcome marker for Trabeculotomy.
    Goda E; Hirooka K; Mori K; Kiuchi Y
    BMC Ophthalmol; 2019 Dec; 19(1):243. PubMed ID: 31791272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ripasudil: first global approval.
    Garnock-Jones KP
    Drugs; 2014 Dec; 74(18):2211-5. PubMed ID: 25414122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rho-associated protein kinase inhibitor induced morphological changes in type VI collagen in the human trabecular meshwork.
    Okamoto M; Nagahara M; Tajiri T; Nakamura N; Fukunishi N; Nagahara K
    Br J Ophthalmol; 2020 Mar; 104(3):392-397. PubMed ID: 31201167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, efficacy, and patient selection of ripasudil in patients with uncontrolled glaucoma with maximum conventional medical therapy.
    Jethva J; Bhagat P; Prajapati K; Tank G
    Indian J Ophthalmol; 2022 Jun; 70(6):2020-2023. PubMed ID: 35647972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morphological Changes of Human Corneal Endothelial Cells after Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Administration: A Prospective Open-Label Clinical Study.
    Nakagawa H; Koizumi N; Okumura N; Suganami H; Kinoshita S
    PLoS One; 2015; 10(9):e0136802. PubMed ID: 26367375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corneal sterile infiltration induced by topical use of ocular hypotensive agent.
    Manabe Y; Sawada A; Mochizuki K
    Eur J Ophthalmol; 2020 Sep; 30(5):NP23-NP25. PubMed ID: 31096781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.
    Inoue T; Tanihara H
    Expert Opin Pharmacother; 2017 Oct; 18(15):1669-1673. PubMed ID: 28893104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allergic contact dermatitis caused by topical eye drops.
    Spaeth GL
    Am J Ophthalmol; 2006 Oct; 142(4):706. PubMed ID: 17011880
    [No Abstract]   [Full Text] [Related]  

  • 31. Descemetorhexis Without Grafting for Fuchs Endothelial Dystrophy-Supplementation With Topical Ripasudil.
    Moloney G; Petsoglou C; Ball M; Kerdraon Y; Höllhumer R; Spiteri N; Beheregaray S; Hampson J; DʼSouza M; Devasahayam RN
    Cornea; 2017 Jun; 36(6):642-648. PubMed ID: 28476048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits.
    Ohta Y; Takaseki S; Yoshitomi T
    Jpn J Ophthalmol; 2017 Sep; 61(5):423-432. PubMed ID: 28653193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allergic Contact Dermatitis Due to Ripasudil Hydrochloride Hydrate in Eye-drops: A Case Report.
    Kusakabe M; Imai Y; Natsuaki M; Yamanishi K
    Acta Derm Venereol; 2018 Feb; 98(2):278-279. PubMed ID: 29110016
    [No Abstract]   [Full Text] [Related]  

  • 34. Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Transiently Alters the Morphology of Corneal Endothelial Cells.
    Okumura N; Okazaki Y; Inoue R; Nakano S; Fullwood NJ; Kinoshita S; Koizumi N
    Invest Ophthalmol Vis Sci; 2015 Nov; 56(12):7560-7. PubMed ID: 26618648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of the Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) on Corneal Endothelial Wound Healing.
    Okumura N; Okazaki Y; Inoue R; Kakutani K; Nakano S; Kinoshita S; Koizumi N
    Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):1284-92. PubMed ID: 26998714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of ripasudil as an adjunct treatment in the management of pseudoexfoliative glaucoma.
    Mohapatra S; Thakur S; Panda BB; Das P
    Indian J Ophthalmol; 2023 Jul; 71(7):2756-2759. PubMed ID: 37417116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
    Am J Ophthalmol; 2013 Oct; 156(4):731-6. PubMed ID: 23831221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction Between Pilocarpine and Ripasudil on Intraocular Pressure, Pupil Diameter, and the Aqueous-Outflow Pathway.
    Yamagishi-Kimura R; Honjo M; Komizo T; Ono T; Yagi A; Lee J; Miyata K; Fujimoto T; Inoue T; Tanihara H; Nishida J; Uchida T; Araki Y; Aihara M
    Invest Ophthalmol Vis Sci; 2018 Apr; 59(5):1844-1854. PubMed ID: 29677344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
    Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
    Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ripasudil Hydrochloride Hydrate in the Treatment of Glaucoma: Safety, Efficacy, and Patient Selection.
    Kusuhara S; Nakamura M
    Clin Ophthalmol; 2020; 14():1229-1236. PubMed ID: 32440089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.